MIRA Pharmaceuticals Progresses MIRA-55 and SKNY-1 Toward IND-Enabling Studies
MIRA Pharmaceuticals announced progress on its lead preclinical programs MIRA-55 and SKNY-1, advancing them toward IND-enabling studies through formulation optimization and CMC activities. The firm completed in-life dosing and necropsy phases of exploratory toxicology studies in rats and dogs to inform the design of future GLP-compliant studies.
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.